Trillium Therapeutics (TSX:TRIL): A Pharma Stock With Huge Upside Potential

Trillium Therapeutics is a pharmaceutical company with massive upside potential for its innovative cancer treatment therapies.

| More on:
Test tubes

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Trillium Therapeutics (TSX:TRIL)(NASDAQ:TRIL) is a Canadian pharmaceutical stock that has massive upside potential and should be on your radar right now. The clinical-stage immuno-oncology company is developing revolutionary cancer treatment therapies, and it could be an excellent value pick for investors today.

I will discuss the company and why its stock could be an ideal investment for you to consider.

A leading innovator in oncology

Trillium Therapeutics may not be as big a name as Pfizer, but it is not a company to shrug aside. The company aims to become a leading innovator in oncology by using innovative therapies targeting immune-regulatory pathways used by tumour cells to steer clear of the immune system.

Trillium has a comprehensive and differentiated approach to targeting cancer cell therapy. The company is currently focusing on advancing the clinical development of TTI-621 and TTI-22 — two of its most advanced products for its innovative cancer cell treatment therapy.

The company is currently trying to determine the maximum tolerated doses for both products. Trillium is aiming to focus its clinical programs based on promising results for both products.

Trillium has identified that its fusion proteins can be effective in treating a wide range of cancers. CD47 is a type of immunoglobulin that exists on the surface of many cancer cells. This immunoglobulin is expressed by several solid and liquid tumours. Typically, the high expression is correlated with worse clinical outcomes.

Trillium has already identified several cancers that saw positive responses in patients to TTI-621. Considering the promising signs displayed by TTI-621, Trillium is planning to combine both products with other anti-cancer drugs and evaluate the performance of its cancer treatment therapies.

Patented-protected intellectual property

It is safe to say that Trillium owns intellectual property that could be priceless. It owns and controls patent rights covering key products and therapeutic end uses. Trillium has multiple patents and patent applications either approved or pending approval in major pharmaceutical markets worldwide. The company’s hoard patents include inventions in different areas that could give it the edge in the industry.

Trillium primarily owns two patent families. The first one relates to the applications for TTI-621 and TTI-622 for cancer treatment. The other patent family is related to the company’s drug as a composition of matter. The company has also filed for patents that protect additional inventions related to both its major products, including anti-cancer drug combination therapies that use biomarkers to determine responders.

Expert regulatory process navigation

Trillium has filed patent applications within corresponding jurisdictions worldwide to protect its intellectual property. Its expertise in navigating regulatory processes has allowed Trillium to gain approvals throughout the U.S., Europe, Canada, and other commercial territories. The company has a competitive edge over its peers.

Foolish takeaway

Trillium is not as massive a name in the international Big Pharma industry. However, the stock could be valuable for long-term investors if the company successfully develops its innovative cancer treatment therapies.

If you are bullish on its ability to succeed, it could be an excellent value investment for your portfolio.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Investing

TFSA and coins

3 Oversold Stocks to Buy for a TFSA

Manulife Financial (TSX:MFC)(NYSE:MFC) and two other oversold TSX stocks could be top long-term holds for a TFSA retirement fund.

Read more »

protect, safe, trust
Stocks for Beginners

2 Safe Stocks Beginners Can Buy for Reliable Passive Income

If you are a beginner investor looking for safe, reliable passive income, I've got two TSX stocks you can rely…

Read more »

Dollar symbol and Canadian flag on keyboard
Dividend Stocks

2 Oversold Great Canadian Dividend Stocks to Buy Now and Own for 20 Years

These top Canadian dividend stocks look oversold right now and continue to raise their payouts.

Read more »

Man holding magnifying glass over a document
Dividend Stocks

3 Value TSX Stocks to Eye in July 2022

Here are a few value TSX stocks to check out in July 2022. They also pay juicy, safe dividend income…

Read more »

sad concerned deep in thought

Elon Musk Buys Dogecoin: Should You?

Elon Musk is back to buying Dogecoin (CRYPTO:DOGE). Should you join him?

Read more »

analyze data
Dividend Stocks

2 Canadian Stocks at the Top of My Buy List

Here are two of the top Canadian stocks on my buy list, as the market uncertainty continues to plague Canadian…

Read more »

question marks written reminders tickets

Oil Stocks vs. Gold: Which Is Better for a Recession?

Gold is considered a good asset to hold in recessions, but oil stocks like Cenovus Energy (TSX:CVE)(NYSE:CVE) are doing better…

Read more »

gas station, convenience store, gas pumps

Is Alimentation Couche-Tard (TSX:ATD) Stock a Buy After Disappointing Earnings?

Alimentation Couche-Tard (TSX:ATD) had a challenging fourth quarter, but there are still plenty of reasons to like this stock long…

Read more »